Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 3

Interventions

Dexamethasone 27Melphalan 22Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 14Filgrastim 13Bortezomib 12Calcium Dobesilate 9Lenalidomide 7fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Cyclosporine 5Thalidomide 4Interferon-alpha 4Etoposide 4Busulfan 4miridesap 3dexamethasone acetate 3Radiotherapy 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Carboplatin 3pomalidomide 2liposomal amphotericin B 2ixazomib 2daratumumab 2birtamimab 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Immunoglobulin Light-chain Amyloidosis × miridesap × Clear all
NCT01777243 2018-07-24

A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

GlaxoSmithKline

Phase 1 Completed
25 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01406314 2017-06-09

SAP Depleter Dose Assessment Study in Patients

GlaxoSmithKline

Phase 1 Completed
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02953808 2017-01-19

Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

GlaxoSmithKline

Phase 1 Completed
18 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡